Article
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
The Journal of antimicrobial chemotherapy - 1 Jun 2020
El Bouzidi Kate, Kemp Steven A, Datir Rawlings P, Murtala-Ibrahim Fati, Aliyu Ahmad, Kwaghe Vivian, Frampton Dan, Roy Sunando, Breuer Judith, Sabin Caroline A, Ogbanufe Obinna, Charurat Man E, Bonsall David, Golubchik Tanya, Fraser Christophe, Dakum Patrick, Ndembi Nicaise, Gupta Ravindra K
Abstract excerpt
OBJECTIVES: HIV-1 integrase inhibitors are recommended as first-line therapy by WHO, though efficacy and resistance data for non-B subtypes are limited. Two recent trials have identified the integrase L74I mutation to be associated with integrase inhibitor treatment failure in HIV-1 non-B subtypes. We sought to define the prevalence of integrase resistance mutations, including L74I, in West Africa. METHODS: We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.